[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basal-cell-carcinoma-bcc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basal-cell-carcinoma-bcc":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,79,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627953","phase-2-flash-radiotherapy-for-skin-cancer-100627953",false,"NCT07455331","Flash Radiotherapy for Skin Cancer","Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Participants With Localized Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma","LANCE","Inclusion Criteria:\n\n1. Signed study Informed Consent Form\n2. Karnofsky Performance Status (KPS) ≥ 60\n3. Age ≥ 60 years\n4. Participants with histologically proven cSCC; or participants with BCC either histologically proven or proven by non-invasive imaging: either OCT, LC-OCT or RCM\n5. Participants requiring radiotherapy treatment according to the dermato-oncology tumor board: participants who cannot undergo surgical procedure or participants who decline surgical resection, and\u002For anatomical locations where surgery can compromise function or cosmesis.\n6. T1-N0 lesions (TNM UICC, 8th Edition)\n7. Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated\n8. In cases of prior intervention within the target area, the treated lesion must be located at a distance of \\> 4 cm from the previous site.\n\nExclusion Criteria:\n\n1. Previous radiotherapy in the treated area or a history of radiation therapy within 4 cm of the lesion to be treated\n2. Concomitant auto-immune disease with skin lesions\n3. Concomitant use of radio-sensitizer drug\n4. Cognitive disorders not compatible with the signature of informed consent or that may compromise compliance with the requirements of the study\n5. Current, recent (within 10 days prior to start of study treatment), or planned participation in an experimental drug study (before EOT visit)\n6. Concomitant use of systemic or immunochemotherapy for skin cancer(s)\n7. Concomitant use of systemic chemotherapy for a cancer other than the skin cancer(s)\n8. Topical antitumoral treatment is prohibited within the radiation field except after a mandatory 4-weeks washout period.\n9. Any active cutaneous infection within the irradiation field (except if completely resolved prior to the initiation of radiotherapy).\n10. Uncontrolled intercurrent comorbidities that may impair wound healing including Diabetes Mellitus (HbA1c \\> 8.5% or evidence of active diabetic ulceration), Chronic Venous Insufficiency with active venous ulcers, or severe (Grade 3+) oedema in the treatment field.","ALL","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous Squamous Cell Carcinoma (cSCC) and Basal Cell Carcinoma (BCC). FLASH therapy can deliver the irradiation dose within milliseconds instead of the minutes commonly required in conventional radiotherapy, with the aim of providing a curative dose while minimizing side effects on healthy tissue.\n\nThis is a phase II selection and monocentric clinical investigation with a 1 to 1 randomization. This clinical investigation will include approximately 60 participants aged ≥ 60 years old with one or more localized cSCC and BCC who either cannot undergo surgery or decline surgical resection.\n\nThe study design is the following:\n\n* On day 1, either a single dose FLASH radiotherapy (22 Gy) will be delivered or a single dose conventional radiotherapy (22 Gy) will be delivered to the selected localized cSCC or BCC lesion(s) (up to maximum 3 per participant; all lesions distant of at least 4 cm from one-another).\n* The surveillance period will be of 6 weeks post irradiation.\n* Follow-up visits will take place at 3, 6, and 12 months post-treatment.",[27,28],"Cutaneous Squamous Cell Carcinoma (CSCC)","Basal Cell Carcinoma (BCC)",[30,31,32],"radiotherapy","FLASH","skin cancer","NOT_YET_RECRUITING","2026-05-06",{"date":36,"type":37},"2026-05-11","ACTUAL",{"date":39,"type":21},"2026-06-23",{"date":41,"type":21},"2030-12-23",{"name":43,"class":44},"Jules Bordet Institute","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100591507","phase-2-evaluation-of-efficacy-and-safety-of-cemiplimab-as-first-line-treatment-for-advanced-basal-cell-carcinoma-bcc-patients-100591507","NCT06981325","Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients","Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (CEMI-first) - An Open Label, Single Arm, Prospective Phase II Trial of the DeCOG Network","CEMI-first","Inclusion Criteria:\n\n1. Signed informed consent form available\n2. Patient\\* 18 years or older at time of signing informed consent form\n3. Centrally confirmed histological diagnosis of BCC\n\n   NOTE: Tumor tissue to be sent to Central Pathology during screening procedure:\n   * Formalin-fixed, parrafin-embedded (FFPE) tumor specimen in a paraffin block (preferred) OR\n   * approximately 10 sections (5µm thickness) on uncoated slides and 10 sections (5µm thickness) on Superfrost Ultra slides containing unstained, freshly cut, serial sections to be submitted along with associated pathology report (please refer to section 11.1.1 for details)\n4. Locally advanced stage without distant metastases, not amenable for surgery or radiotherapy or surgery\u002Fradiotherapy contraindicated or refused by patient (as evidenced in source data)\n5. Expected survival of at least 6 months\n6. ECOG performance status 0 or 1\n7. Adequate laboratory parameters particularly for the blood count, renal and liver function parameters.\n\n   1. Absolute number of neutrophils ≥ 1.5 x 109\u002FL\n   2. Platelets ≥ 75 x 109\u002FL\n   3. Hemoglobin ≥ 9 g\u002FdL\n   4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)\n   5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN\n   6. AP ≤ 2.5x ULN\n   7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL\u002Fmin\n8. Absence of other severe comorbidities\n9. Resolution of any acute, clinically significant treatment-related adverse events from prior therapy\u002Fprocedure to Grade ≤ 1 prior to study entry, with the exception of alopecia.\n10. Negative serum pregnancy test done less than or equal to 7 days prior to enrollment, for females of childbearing potential only.\n11. Sexually active women of childbearing potential (WOCBP) and men with WOCBP partners must be prepared to use suitable contraceptive method with a failure rate of \\\u003C 1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab\n\n    * There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently\n\nExclusion Criteria:\n\n1. Pretreatment with systemic immunotherapy (such as PD-1\u002FPD-L1 or CTL4) or targeted therapy (such as hedgehog inhibitor) NOTE: Prior treatment with imiquimod or other topical or intralesional immune modulators will not be exclusionary\n2. Any other non-radiation anti-cancer therapy (e.g. imiquimod, photodynamic therapy; neither investigational nor standard of care) within 30 days (from date of last administration) of initial Cemiplimab administration or if planned during the study duration\n3. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required systemic immunosuppressive therapy, excluding: vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism requiring only hormone replacement, or psoriasis that does not require systemic treatment\n4. Other neoplasia, in particular hematologic diseases that might impair immune response, such as chronic lymphocytic leukemia, myelodysplastic or myeloproliferative disease and patients with Gorlin-Goltz syndrom\n5. Immunosuppressive corticosteroid doses (\\> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of Cemiplimab NOTE: Patients who require brief courses of steroids (e.g., as prophylaxis for imaging studies due to hypersensitivity to contrast agents) are eligible for participation. Furthermore, patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or replacement in case of adrenal or hypophysis insufficiency are eligible for participation.\n6. Known allergic\u002Fhypersensitive reaction to the study drug and any of its excipients or history of documented allergic\u002Fhypersensitive reactions to antibody treatments\n7. Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.\n\n   NOTE: Patients are eligible if:\n   * Patients have controlled HIV infection with CD4 counts is \\> 350 cells\u002FµL and viral load is undectable \\[HIV RNA PCR\\]\n   * Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undectable serum viral load \\[HBV DNA PCR\\]. Patients must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab\n   * Patients positive for HCV antibody have controlled HCV infection with undectable viral load \\[HCV RNA PCR\\]\n8. History of pneumonitis within the last 3 years\n9. Patients with history of solid organ transplant (patients with prior corneal transplants may be allowed to enroll after discussion with and approval from the Lead Investigator)\n10. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n11. Receipt of live vaccines (including attenuated) within 30 days of first administration of Cemiplimab\n12. Pregnancy or lactation period.\n13. Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent.\n14. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results\n15. Legal incapacity or limited legal capacity.\n16. On-treatment participation in another clinical trial in the period 30 days prior to start of the study treatment and during the study","18 Years",{"count":56,"type":21},34,[24],"The study is an open-label, singel arm, prospective, multicenter phase II trial evaluating the efficacy and safety of Cemiplimab when applied as first-line therapy in patients with locally advanced basal cell carcinoma (BCC), which were not pretreated with hedgehog inhibitors (HHI).",[28,60],"First Line Treatment",[62,63,64,65,66,67],"BCC","Skin Cancer","Basal Cell Carcinoma","anti-PD-1 monoclonal antibody","HHI naïve","Cemiplimab","RECRUITING","2026-03-10",{"date":71,"type":37},"2026-03-11",{"date":73,"type":37},"2025-08-07",{"date":75,"type":21},"2029-07",{"name":77,"class":44},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest",7,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100563979","phase-1-blue-light-photodynamic-therapy-and-sonidegib-for-multiple-basal-cell-carcinomas-100563979","NCT06623201","Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas","Patients will be included in the study based on the following criteria:\n\n1. Male or females, at least 18 years of age.\n2. Diagnosis of BCC with at least 3 nodular lesions that measure 0.5 cm to 5 cm in diameter, located on the head and neck, trunk or extremities.\n3. Diagnosis must be confirmed clinically at baseline with 1-3 lesions having been biopsied no sooner than 2 weeks prior to treatment.\n4. Patients who may have high burden of disease (i.e., large lesions), who are non-surgical candidates or who refuse surgery.\n5. Non-surgical candidates, who may be able to undergo resection of selected single, individual lesion, but may not tolerate extensive surgery, may have many co morbidities, may be prone to complications.\n6. Patients in whom surgery or radiation therapy may be impractical.\n7. Primary lesions may be acceptable for enrollment.\n8. Within normal limit hematopoietic capacity, hepatic and renal function. Values outside those limits may be allowed at the discretion of the PI, if they are determined as not clinically significant.\n9. Evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial.\n10. Ability to understand and the willingness to sign a written informed consent document in English.\n\nExclusion Criteria\n\nPatients will be excluded from the study based on the following criteria:\n\n1. Sexually active women of childbearing (WOCBP)\\* who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for 20 months after the final dose of treatment. Highly effective contraceptive measures include:\n\n   1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation\n   2. Intrauterine device (IUD); intrauterine hormone-releasing system\n   3. Bilateral tubal ligation;\n   4. Vasectomized partner (provided that the vasectomized partner is the sole sexual partner of the WOCBP study subject);\n   5. and\u002For sexual abstinence.\n\n      * Childbearing potential refers to a female who has reached menarche, has not had a surgical sterilization procedure (such as a hysterectomy or bilateral oophorectomy), and is not postmenopausal. Menopause is defined as 12 consecutive months of amenorrhea without other biological causes. Furthermore, for females under 55 years old, a serum follicle-stimulating hormone level greater than 40 mIU\u002FmL must be documented to confirm menopause.\n2. Sexually active males who are unwilling to use a condom with female partners of childbearing potential, during the study, and for at least 8 months after the last dose of treatment.\n3. Subjects who plan on donating blood or blood products during the study and for at least 20 months after the last dose of treatment. Male subjects must agree not to donate sperm during the study and for at least 8 months after the last dose of treatment.\n4. Target lesions of basal cell carcinomas of aggressive subtypes (infiltrative, morpheaform, micronodular).\n5. Any BCC that may require Mohs surgery for definitive control as a target lesion.\n6. Subjects with porphyria's or known hypersensitivity to porphyrins.\n7. Subjects with known photosensitivity diseases.\n8. Subjects previously treated with a systemic photosensitizer within 4 months of screening date.\n9. Subjects who desire to get pregnant a female of childbearing potential within the next 1.5 years.\n10. Uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n11. Life expectancy less than one year.\n12. Inability or unwillingness to swallow capsules.\n13. Have a history of alcohol of substance abuse, unless in full remission for greater than 6 months prior to the screening visit (Day 0) when the consent form is signed.\n14. Having used any of the following treatment within 6 months before the baseline visit:\n\n    * hedgehog pathway inhibitor, biologics, or chemotherapy\n    * topical chemotherapy agents including Imiquimod, fluorouracil,) to the selected treatment lesion sites within 3 weeks.\n15. Currently undergoing treatment with photodynamic therapy within 3 weeks before baseline visit.\n16. Subjects who have received any type of solid organ transplant.\n17. Subjects taking immunosuppressive medications at the screening visit that interact with Sonidegib at the screening visit unless approved by the investigator..\n18. Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and\u002For during study participation. Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.\n19. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n20. Subjects unable or unwilling to comply with the study visit schedule and requirements of the study.\n21. Subjects unable to speak and read the English language.\n22. A subject who, in the opinion of the sponsor-investigator will be uncooperative or unable to comply with study procedures.\n23. A subject who, in the opinion of the sponsor-investigator will be uncooperative or unable to comply with study procedures.",{"count":86,"type":21},20,[88],"PHASE1","This research study is testing combination Blue-light photodynamic therapy and Sonidegib as a possible treatment for people with multiple basal cell carcinoma lesions.\n\nBasal cell carcinoma lesions are typically treated by freezing the lesion or surgically removing the lesion. These types of treatment can cause scarring. Photodynamic therapy uses light along with a drug applied to the skin to kill the cancer cells and cause them to break apart. The light used can cause the skin to feel warm, but does not cause scarring.",[28],[92,93,94],"Basal cell carcinoma","Levulan","PDT","2026-01-27",{"date":97,"type":37},"2026-01-29",{"date":99,"type":37},"2024-10-07",{"date":101,"type":21},"2026-12-01",{"name":103,"class":44},"Nathalie Zeitouni",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":45},"100620749","impact-of-preoperative-high-frequency-ultrasound-cutaneous-lesion-extent-assessment-on-excision-margin-positivity-in-head-and-neck-skin-cancer-and-the-relationship-between-preoperative-assessment-methods-inadequate-excision-margins-and-tumor-recurrence-100620749","NCT07361666","Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence (HFUS-CLEAR)","HFUS-CLEAR","Inclusion Criteria:\n\n* Cutaneous lesion located in the head and neck region with a preoperative diagnosis of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), established by dermoscopy or biopsy, and qualified for surgical excision with curative intent.\n* patient age of 18 years or older.\n* Ability of patient to provide voluntary, informed, written consent for participation in the study.\n* Confirmation that the patient has read and understood the Patient Information Sheet.\n\nExclusion Criteria:\n\n* Excisional biopsies without radical intent.\n* Lack of histopathologic confirmation of BCC or SCC in the postoperative specimen (incorrect dermoscopic qualification).\n* Inability to perform radical surgical excision due to excessive tumor extent, poor general condition of the patient, or lack of patient consent for surgery.\n* Pregnancy.",{"count":113,"type":21},400,"OBSERVATIONAL","Non-melanoma skin cancers (NMSC), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in Caucasians, with the majority of tumors located in the head and neck due to chronic ultraviolet exposure. Although BCC has very low metastatic potential, while cSCC carries a higher risk of nodal spread, both can cause significant local tissue destruction and functional and cosmetic impairment. Complete excision with histologically clear margins remains the standard treatment; however, incomplete or close excision margins are reported in a substantial proportion of cases and are associated with increased risk of local recurrence, need for additional treatment, and higher healthcare costs.\n\nPreoperative dermoscopy improves delineation of lateral tumor borders but does not assess depth of invasion. High-frequency ultrasound (HFUS) is a rapid, non-invasive imaging modality that can visualize superficial skin structures and estimate tumor thickness. Previous studies have suggested good agreement between HFUS and histopathologic depth of invasion, but results are not fully consistent, and HFUS has not yet been incorporated into major guideline recommendations for preoperative assessment of NMSC. Further prospective data are needed to clarify whether HFUS can improve surgical planning and margin control.\n\nThis prospective study is designed to assess the impact of adding preoperative HFUS to standard dermoscopic evaluation in head and neck BCC and cSCC. The primary objectives are: (1) to compare the frequency of positive or inadequate (\\\u003C1 mm) histopathologic excision margins between lesions assessed with dermoscopy alone and those assessed with both dermoscopy and HFUS; and (2) to evaluate 5-year local recurrence rates in relation to preoperative assessment method, histopathologic margin status, and subsequent management of inadequate margins (observation, non-surgical treatment, or scar excision). Secondary and additional objectives include: assessing concordance between HFUS-measured and histopathologic depth of invasion; determining the frequency of residual tumor in scars excised after inadequate margins; evaluating recurrence rate according to the site of inadequate margins (lateral vs deep); and identifying patient-related, tumor-related, surgical, and histopathologic predictors of inadequate margins and recurrence. Approximately 400 lesions (BCC or cSCC of the head and neck) qualified for curative surgical excision will be included. Each lesion will constitute an independent study case. All lesions will undergo preoperative assessment, including clinical evaluation with detailed medical history and dermoscopy; in one cohort, lesions will additionally be evaluated with HFUS. HFUS will be performed with an 18-MHz linear probe, using superficial B-mode and color Doppler. Maximum tumor depth will be recorded from the epidermal surface (or granular layer) to the deepest hypoechoic point, with assessment of potential infiltration of deeper structures when visible. Surgical excision and postoperative care will follow standard clinical practice. Postoperative histopathologic assessment of FFPE tumor samples will record tumor histologic type and subtype, margin status, width, depth of invasion, differentiation, inflammation, elastosis, perineural or vascular invasion, and other routinely assessed diagnostic features. In the event of positive or inadequate excision margins, patients will be referred, after consultation with a dermatologist, for further management (observation, non-surgical treatment, or scar excision), depending on clinical indications and patient preferences. Participation in the study will not influence the primary surgical treatment or any decisions regarding subsequent management.\n\nPatients will be followed for at least 5 years according to current clinical guidelines, with dermoscopic skin examination and documentation of local recurrence and its management. The study aims to determine whether incorporating HFUS into preoperative assessment can reduce the frequency of inadequate histologic margins and improve long-term local control in head and neck NMSC.",[117,27,118,119,28,120,121],"Basal Cell Carcinoma of Skin","Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)","Cutaneous Squamous Cell Carcinoma of the Head and Neck","Basal Cell Carcinoma of the Head and Neck","Non-Melanoma Skin Cancer (NMSC)",[64,123,63,124,125,126,127,128,129],"Squamous Cell Carcinoma","Skin Neoplasms","Margins of Excision","Positive Surgical Margins","Recurrence","high-frequency ultrasound","HFUS","2026-01-15",{"date":132,"type":37},"2026-01-23",{"date":134,"type":21},"2025-12-23",{"date":136,"type":21},"2033-11-30",{"name":138,"class":139},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV"]